SAE Rate Higher With Nilotinib Versus Placebo in Parkinson Disease

TUESDAY, Dec. 17, 2019 -- Among patients with moderately severe Parkinson disease, exploratory biomarkers are altered in response to nilotinib, but the rate of serious adverse events (SAEs) is significantly higher in those receiving nilotinib versus...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news